FORMULATION AND IN VITRO EVALUATION OF ORAL DISINTEGRATING TABLETS OF TELMISARTAN
Telmisartan is an anti-hypertensive agent, angiotensin II receptor (AT1) antagonist used in the treatment of hypertension, congestive heart failure and diabetic nephropathy. It has 42% oral bioavailability due to poor aqueous solubility that makes absorption and dissolution rate limited. In the present study, to develop orally disintegrating tablets of Telmisartan with an objective to achieve rapid disintegration, dissolution/absorption and further improving the bioavailability of the drug. Also, to resolve the swallowing problems in paediatric, geriatric patients by rapid disintegration in saliva and improve the patient compliance. Oral disintegrating tablets prepared by direct compression method using super disintegrants like crospovidone (CP), croscarmellose sodium (CCS), sodium starch glycolate (SSG) and combination of super disintegrants in different concentrations. The prepared batches of tablets were evaluated for hardness, weight variation, thickness, friability, drug content, disintegration time, wetting time, water absorption ratio, in vitro dispersion time, and in vitro dissolution profile. Among the prepared formulations F11 containing CP+CCS 6% was considered to be the best formulation, which releases up to 99.15 ± 0.60% of the drug in 25 min and disintegration time is 13.5±0.41 sec. and when the formulation F3 containing combination of CP 9% was considered to be the best formulation, which releases up to 99.65 ± 1.42% of the drug in 30 min and disintegration time is 15.3 ± 0.89 sec.